Drug Profile
RWJ 442831
Alternative Names: RWJ-442831Latest Information Update: 29 Aug 2007
Price :
$50
*
At a glance
- Originator Essential Therapeutics [CEASED]
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Cephalosporins; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections pharmacodynamics section
- 04 Oct 2004 Essential Therapeutics has closed down
- 24 Sep 2003 Preclinical data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the pharmacokinetics section ,